Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MethylGene has enrolled its first patient in a single-agent phase II clinical trial for the treatment of Hodgkin's lymphoma. This has resulted in payments from the company's partners, Pharmion Corporation and Taiho Pharmaceutical, of $4 million and $1.5 million, respectively.
Subscribe to our email newsletter
In this open-label trial the histone deacetylases (HDAC) inhibitor MGCD0103 will be given orally at a dose of 110mg, three times per week, to patients with Hodgkin’s lymphoma who have failed other treatments or whose disease has relapsed.
Key objectives of the study will be to determine the effectiveness of MGCD0103 as a treatment option for patients with refractory or relapsed Hodgkin’s lymphoma. Effectiveness, or the success rate, will be measured by the combined total of complete responses, partial responses and patients who experience stable disease for six cycles or more (a cycle is equal to four weeks).
Secondary objectives include determining the safety profile, as well as assessing biomarkers and predictive markers for MGCD0103. The study is expected to enroll up to 35 patients at several leading cancer centers in North America and take approximately 12 to 15 months to complete.
“We are pleased to be steadily moving our HDAC cancer program forward and the initiation of this first phase II trial of our lead product candidate is an important achievement, resulting in $5.5 million of milestone payments. In addition to studying MGCD0103 in Hodgkin’s lymphoma, we expect to embark, with our partners Pharmion and Taiho, on additional phase II trials with our compound in other cancer indications where epigenetics appears to play a role,” commented Donald Corcoran, president and CEO of MethylGene.